



HEMATOLOGY, TRANSFUSION AND CELL THERAPY

www.htct.com.br


Case Report

The role of allogeneic stem cell transplantation in severe erythropoietic protoporphyria in adults and young adults: timing and modalities

Camilla Frieri ^{a,b,*}, Antoine Poli ^c, Marie Balsat ^d,
Flore Sicre de Fontbrune ^a

^a Hematology Transplant Unit, Saint-Louis Hospital, APHP, Paris, France

^b Hematology Unit, AORN San Giuseppe Moscati Hospital, Avellino, Italy

^c CRM R Porphyries, Louis-Mourier Hospital, APHP, Colombes, France

^d Service d'Hématologie, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France

ARTICLE INFO

Article history:

Received 22 August 2023

Accepted 27 February 2024

Available online xxx

Keywords:

Erythropoietic protoporphyria

Congenital erythropoietic porphyria

Hematopoietic stem cell

transplantation

Liver transplantation

Introduction

Porphyrias are caused by enzymatic dysfunctions in the haem biosynthesis metabolic pathway.¹

Erythropoietic protoporphyria (EPP), the most common porphyria in children, that occurs in about 1 in 74,300 individuals, is an autosomal disorder, characterized by acute, severe, non-blistering phototoxicity within minutes of exposure by sunlight, and caused by pathogenic variants in the ferrochelatase (FECH) gene.^{2,3} The reduced enzyme activity results in the accumulation, during erythropoiesis, of protoporphyrin IX

(PPIX), which activated by sunlight exposure, generates singlet oxygen and radical reactions, leading to tissue damage and excruciating pain.

PPIX is excreted solely through the hepatobiliary route, and in case of accumulation can aggregate in hepatocytes and precipitate in bile canaliculi, causing severe hepatotoxicity, that may require liver transplantation (LT).^{4–6} However persistence of PPIX accumulation in the bone marrow causes the recurrence of liver disease in most patients, justifying sequential hematopoietic stem cell transplantation (HSCT) and LT to cure EPP-related hepatopathy.^{7,8}

Congenital erythropoietic porphyria (CEP) is a rare autosomal recessive disorder caused by a deficiency in uroporphyrinogen III synthase (UROS), leading to the accumulation of type I porphyrins during erythropoiesis. The prognosis is poor

* Corresponding author.

E-mail address: camillafrieri@gmail.com (C. Frieri).

<https://doi.org/10.1016/j.htct.2024.02.027>

2531-1379/© 2024 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

in severely affected patients due to the destruction of subcutaneous tissues and pancytopenia. Death often occurs early in adulthood.^{9,10} Since the 1990s, HSCTs have been the therapeutic choice for severe pediatric cases (Table 1).

Here, we present four patients with either EPP or CEP who underwent HSCT after the age of fifteen.

Clinical cases

Patient #1 was a 17-year-old EPP-patient who underwent a LT from his father in 2001, in the context of EPP-related hepatopathy. After five months, the patient underwent HSCT from the same haploidentical donor. The conditioning regimen was based on fludarabine and total body irradiation (TBI 2cGY). HSCT was complicated by primary graft failure. He continued transfusions and ferrochelating therapy to prevent hemochromatosis. He died 11 years later.

Patient #2, a 32-year-old man diagnosed with EPP at the age of three, underwent a first LT in 2009 for liver cirrhosis. In the following years, he presented a progressive worsening of liver function and a liver biopsy in 2013 confirmed the recurrence of the initial disease (micro-nodular cirrhosis, with a very strong fibrotic component and pigment overload typical of PPIX deposition).

He therefore underwent a second LT, followed by a HSCT, to prevent EPP recurrence on the graft. The patient underwent a non-myeloablative matched-unrelated transplant after conditioning with fludarabine, busulfan and thymoglobulin. He demonstrated excellent neutrophil engraftment on day +19. Peripheral blood donor chimerism was 100% by day +30. He did not have any signs of GvHD or infectious complications. His blood counts were normal. Free erythrocyte PPIX levels were normal and he did not experience any photosensitivity. Nine years after HSCT, he is alive but he underwent a third LT for arterial stenosis and severe infectious complications on second liver transplant.

Patient #3 was a woman diagnosed with EPP at the age of five, which only presented regular mild episodes of photosensitivity. At the age of 40, she experienced a first severe cholestatic hepatitis episode and was treated with ursodeoxycholic acid for six months. The cholestasis resolved and PPIX levels dropped to pre-hepatitis levels.

Eight months later, a second severe episode of cholestatic hepatitis occurred (bilirubin up to 500 $\mu\text{mol/L}$), requiring prolonged hospitalization in an intensive care unit. Hydroxycarbamide, red blood transfusions and plasma exchanges contributed to suppress endogenous hematopoiesis and the production of porphyrins, allowing full recovery. Liver biopsy showed a parenchyma of respected architecture, with portal fibrosis and discrete steatosis, and pigment overload typical of PPIX deposition.

She was referred for an allogeneic HSCT from a 10/10 HLA-matched unrelated donor. Conditioning regimen, preceded by desensitization protocol by plasma exchanges, intravenous immunoglobulin and rituximab (donor specific antibody higher than 12,000 mean fluorescence intensity (MFI) by single antigen bead assay), consisted of fludarabine, busulfan and thymoglobulin.

Neutrophil engraftment occurred on day +24 and peripheral blood donor chimerism was 94.2% by day +30 and 96% by day +100. There were no GvHD or infectious complications. Free erythrocyte protoporphyrin and the plasma-free protoporphyrin were repeated and dropped to normal levels at day 28 after HSCT (Figure 1). She had complete resolution of photosensitivity and she largely returned to a normal life. With 22 months of follow up, the patient is fine, with only mild persistent thrombocytopenia.

Patient #4 was diagnosed with CEP at the age of two, mostly with skin involvement. At four years old, he underwent a first matched-unrelated allogeneic HSCT after a myeloablative conditioning regimen. Post-transplantation, his blood count was normal, he did not show any signs of GvHD or infectious complications and he showed a marked improvement in skin lesions. However, after 10 years, he presented with moderate cytopenia, new erosive, bullous skin lesions with scleroderma areas and functional joint impotence. Erythrocyte porphyrins increased to a very high level (24 $\mu\text{mol/L}$) in red blood cells ($n < 1.9$). Peripheral blood chimerism was 76% recipient.

At the age of 22, he underwent a second HSCT from a matched-unrelated donor after a reduce intensity conditioning regimen. He achieved neutrophil engraftment on day +18 and a full donor chimerism. No acute GvHD occurred. Two years after HSCT, the patient leads a normal life, with normal protoporphyrin levels.

Discussion and conclusions

EPP and CEP have great clinical variability related to heterogeneous residual enzymatic activities; while numerous therapies have been applied, HSCT is the only curative treatment for severe forms of the diseases. From 1991, when the first HSCT was performed for CEP, there have been about thirty reports of, mainly pediatric, patients (Table 1).

The four cases we present may expand the already known experience about HSCT in porphyrias, to young adults and adults. Two patients presented the resolution of disease manifestations achieving normal protoporphyrin levels, one had primary graft failure (conditioning regimen was retrospectively not sufficient for engraftment) and the last experienced late secondary graft failure but was rescued by a second transplant. None experienced acute nor chronic GvHD.

HSCT is certainly feasible, from any stem cell source or any type of donor, when the disease is severe. In the past, a myeloablative conditioning regimen was preferred, however engraftment seems to not be lower with non-myeloablative conditioning and minimization of toxicity is a priority in patients with liver failure and non-malignant disease. Hepatic involvement requires careful pre-transplant evaluation, including liver biopsy.

From a metabolic point of view, the efficacy of HSCT depends on the initial level of toxic porphyrin production and on the level of myeloid chimerism reached, i.e., the higher the initial porphyrin production, the lower the level of residual native erythropoietic cells must be for the patient to be asymptomatic. In patient #4, a 76% recipient chimerism was associated with sufficient erythrocyte porphyrins production

Table 1 – Individuals with EPP (erythropoietic protoporphyria) and CEP (congenital erythropoietic porphyria) treated using stem cell transplantation. Patients transplanted after 15 years old are presented in bold.

UPN EPP patient	Ref. ♦	Genotype	Age [†] (years or months)	Sex (F/M)	Country (F/M)	Liver Transplant before HSCT ² (yes/no)	N° of liver transplant	Conditioning regimen (HSCT)	RIC/MAC GvHD prophylaxis	Donor	PPE before/after HSCT	Alive/Dead	Cause of death
#1	---	c.899delTG heterozygous in exon 8 + hypomorphic allele IVS3-48 C/T; p.V300V6X22 exon8	17 yrs	M	France	Yes,	1	Flu- TBI•	RIC	Tacro-MMF Haplo	Primary graft failure	Dead 11 yrs post-HSCT	Progression EPP
#2	---	c.490 C>T p.R164W + c.645G>C p.R215P	23 yrs	M	France	yes	3	Flu-Bu-Thymo•	RIC	CsA-MTX MUD 9/10	389.6 µmol/L 0.8 µmol/L	Alive 9 yrs post-HSCT RD	---
#3	---	Complete deletion of FECH + IVS3-48C	43 yrs	F	France	no	---	Flu-Bu-Thymo•	RIC	CsA- MMF MUD 10/10	295.1 µmol/L 1.9 µmol/L	Alive 22 months post-HSCT RD	---
#5	Poh-Fitzpatrick MB, 2002	Misense mutation C185>G (Pro62>Arg)	47 yrs	F	USA	no	---	Bu-Cy-Etoposide	N/A	CsA-PDN Sibling	N/A	Alive 5 yrs post-HSCT RD	---
#6	McGuire BM, 2005	N/A	N/A	M	USA	yes	2	N/A	N/A	N/A	N/A	Dead 3 mo post-HSCT	Sepsis
#7	Rand EB, 2006	Heterozygous low expression IVS3-48C	12 yrs	M	USA	yes	1	TBI-Cy	MAC	N/A Sibling	N/A	Alive 1 year post-HSCT	---
#8	Wahlin S, 2007	IVS3-48C	62 yrs	M	USA	no	---	Bu-Flu-Cy-Thymo	RIC	Tacro-Stro MUD 10/10	N/A	Alive 30 mo post-HSCT	---
#9	Smiers FJ, 2010	"null allele" mut. (930G>A)	N/A	M	Holland	yes	1	Flu-Cy-Thymo	RIC	CsA-MTX MUD 10/10	N/A	Dead 8 mo post-HSCT	CMV infection
#10	Wahlin S, 2010	Misense mut. FECH	9 yrs	M	England	yes	1	Flu-Treo-Cy-Thymo-Mephalan- Alemtuzumab ⁴	RIC	MMF-PDN Haplo	N/A	Dead	Infectious complications
#11	Cheung CY, 2015	N/A	57 yrs	M	England	yes	1	N/A	N/A	N/A	N/A	Alive 5 months post-HSCT	---
#12	Windon AL, 2017	Heterozygous low expression IVS3-48C [315-348 T>C]	21 yrs	M	Hong Kong	no	---	Flu-Cy-TBI-Thymo	RIC	N/A	N/A	Alive 8 months post-HSCT	---
#4	---	c.205G>A; p.A69T homozygous	4 yrs	M	France	no	---	Flu-Bu-TBI	RIC	Tacro-MTX MUD10/10	N/A	Alive 2 yrs post-HSCT	---
#13	Bennard C, 2020	[c.217T>C, p.(Cys73Arg)]	22 yrs	F	France	no	---	MAC	MAC	CsA-MTX MUD 10/10	816 nmol/L	Alive 2 yrs post-HSCT RD	---
#14	Bennard C, 2020	[c.560A>C, p.(Gln187Pro)]	13 mo	F	France	no	---	Bu-Cy	MAC	CsA-MTX Sibling	N/A	Alive 24 yrs post-HSCT	---
#15	Bennard C, 2020	[c.217T>C, p.(Cys73Arg)]	21 mo	F	France	no	---	Bu-Cy	MAC	CsA-MTX Sibling	N/A	Alive 22 yrs post-HSCT	---
#16	Bennard C, 2020	[c.217T>C, p.(Cys73Arg)]	26 mo	F	France	no	---	Bu-Cy-Thymo	MAC	CsA Haplo	N/A	Alive 3 yrs post-HSCT	---
#17	Bennard C, 2020	[c.217T>C, p.(Cys73Arg)]	13 mo	F	France	no	---	Bu-Cy-Thymo	MAC	CsA MUD 10/10	N/A	Alive 3 yrs post-HSCT	---
#18	Bennard C, 2020	[c.217T>C, p.(Cys73Arg)]	4 mo	M	France	no	---	Bu-Cy-Thymo	MAC	CsA MUD10/10	N/A	Dead	Acute liver failure
#19	Bennard C, 2020	[c.10C>T, p.(Leu04Phe)]	7 mo	F	France	no	---	Flu-Bu-Thymo	MAC	CsA- MMF MUD 10/10	N/A	Alive 3 yrs post-HSCT	---
#20	Bennard C, 2020	[c.217T>C, p.(Cys73Arg)]	40 mo	M	France	no	---	Flu-Bu-Thymo	MAC	CsA- MMF MUD 10/10	N/A	Dead	Hepatic aGVHD; TAM
#21	Bennard C, 2020	[c.634T>C, p.(Ser212Pro)]	8 mo	M	France	no	---	Flu-Bu-Thymo	MAC	CsA- MMF MUD 10/10	N/A	Dead	Hepatic aGVHD; TAM
#22	Kauffman L, 1991	N/A	11 yrs	F	England	no	---	Bu-Cy	MAC	CsA-MTX Sibling	N/A	Dead eight months post-HSCT	CMV infection
#23	Thomas JC, 1996	N/A	22 mo	F	France	no	---	Bu-Cy	MAC	CsA-MTX Sibling	N/A	Alive 1 year post-HSCT RD	---
#24	Zix-Kieffer I, 1996	N/A	30 mo	F	France	N/A	N/A	Bu-Cy	MAC	CsA-MTX Sibling	N/A	Alive 10 months post-HSCT RD	---
#25	Texcan I, 1998	URO synthase missense mutation G188R	4 yrs	F	Turkey	no	---	N/A	MAC	CsA Sibling	N/A	Alive 35 months post-HSCT RD	---
#26	Shaw PH, 2001	N/A	2 yrs	F	USA	no	---	Bu-Cy	MAC	CsA Sibling	N/A	Alive 15 months post-HSCT RD	---
#27	Harada FA, 2001	C73R	2 yrs	F	USA	no	---	N/A	N/A	MUD10/10	N/A	Alive 16 months post-HSCT RD	---
#28	Dupuis-Girod S, 2005	Homozgyous missense mutation A69T	4 yrs	M	France	no	---	Bu-Cy-Thymo	MAC	CsA-MTX MUD10/10	N/A	Alive 3 yrs post-HSCT RD	---
#29	Dupuis-Girod S, 2005	Homozgyous missense mutation A69T	4 yrs	F	France	no	---	Bu-Cy-Thymo	MAC	CsA-MTX MUD10/10	N/A	Alive 2 yrs post-HSCT RD	---
#30	Phillips JD, 2007	GATA 1	3 yrs	M	USA	no	---	N/A	N/A	MUD10/10	N/A	Alive 2 yrs post-HSCT RD	---
#31	Talbree SM, 2007	R219W	7 yrs	F	England	no	---	Flu-Bu-Cy	MAC	CsA Sibling	N/A	Alive 3 yrs post-HSCT RD but cGVHD	---

Table 1 (continued)

UPN	CEP	Ref.	Genotype	Age ¹ (years or months)	Sex (F/M)	Country	Liver Transplant ² (yes/no)	N° of liver transplant	Conditioning regimen (HSCT)	RIC/MAC	GVHD prophylaxis	Donor	Porphyria before/ after HSCT	Alive/Dead	Cause of death
*29	Faraci M, 2008		Homozygous URO synthase 217T>C Cys73Arg	12 yrs	M	Italy	no	—	Bu-Thiotepa-Cy- Thymo	MAC	CsA-MTX	MUD10/10	N/A	Alive 7 yrs post-HSCT RD	—
*30	Lebreuilly-Solier I, 2010		p.Cys73Arg	18 mo	M	France	no	—	N/A	N/A	N/A	MUD 10/10	N/A	Alive 2 yrs post-HSCT RD	—
*31	Singh S, 2012		p.Ala69Thr UROS gene (not spec)	14 yrs	M	India	no	—	Flu-Cy- Thymo	RIC	CsA-MTX	Sibling	N/A	Alive 4 yrs post-HSCT RD	—
*32	Martinez Peinado C, 2013		C73R/C73R (UROS gene)	7 mo	M	Spain	no	—	Bu-Cy-Thymo	MAC	CsA-MTX	MUD 10/10	N/A	Alive 1 yrs post-HSCT RD	—
*33	Karakurt N, 2015		UROS gene GATA-1	5 yrs	M	Turkey	no	—	Bu-Cy	MAC	CsA	Sibling	N/A	Alive 3 yrs post-HSCT RD	—

UPN: unique patient number; Ref.: reference; CsA: cyclosporin; F: female; M: male; MMF: mycophenolate mofetil; Tacro: tacrolimus; MTX: methotrexate; PDN: prednisone; N/A: not available; Flu: fludarabine; Bu: busulfan; Thymo: thymoglobulin; Cy: cyclophosphamide; TBI: Total body irradiation; MUD: matched-unrelated donor; Sro: sirolimus; Haplo: haplo-identical; RD = resolution of disease manifestations; aGVHD: acute graft-versus-host disease; cGVHD: chronic graft-versus-host disease; TAM: transplant associated microangiopathy; RIC: reduced intensity conditioning; MAC: myeloablative conditioning; yrs: years; mo: months

[#] Our patients are in green

* patients from literature; 1: age at HSCT; 2: liver transplant was performed before HSCT; • Conditioning regimen doses of our patients: Flu-TBI: fludarabine (30 mg/m²/day on days -5, -4, -3) and TBI 2 Gy; Bu-Flu- Thymo: fludarabine (30 mg/m²/day on days -5, -4, -3, -2 and -1), busulfan (3.2 mg/kg on days -4 and -3) and thymoglobulin (5 mg/kg on days -2 and -1)

3: Patient #5 underwent HSCT for AML; 4: Patient '9, because of anaphylactic shock after thymo, received melphalan and alemtuzumab in addition.

• Ref: Poh-Fitzpatrick MB, Wang X, Anderson KE et al. Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation for myelogenous leukemia in a patient heterozygous for ferrochelatase gene mutations. *J Am Acad Dermatol.* 2002; 46: 861–866.

McGuire BM, Bonkovsky HL, Carithers Jr RL et al. Liver transplantation for erythropoietic protoporphyria. *Liver Transpl* 2005; 11: 1590–1596.

Rand EB, Bunin N, Cochran W et al. Sequential liver and bone marrow transplant- ation for treatment of erythropoietic protoporphyria. *Pediatr* - trics 2006; 118: e1896–e1899.

Smiers FJ, Van de Vijver E, Delsing BJ, et al. Delayed immune recovery following sequential orthotopic liver transplantation and haploidentical stem cell transplantation in erythropoietic protoporphyria. *Pediatr Transplant.* 2010 Jun;14(4):471-5. doi: 10.1111/j.1399-3046.2009.01233.x. Epub 2009 Sep 7. PMID: 19735434.

Cheung CY, Tam S, Lam CW et al. Allogeneic haematopoietic stem cell transplantation for erythropoietic protoporphyria: a cautionary note. *Blood Cells Mol Dis.* 2015 Mar;54(3):266-7. doi: 10.1016/j.bcmd.2014.11.009. Epub 2014 Nov 26. PMID: 25488614.

Windon AJ, Tandon R, Singh et al. Erythropoietic protoporphyria in an adult with sequential liver and hematopoietic stem cell transplantation: A case report. *Am J Transplant.* 2018 Mar;18(3):745-749. doi: 10.1111/ajt.14581. Epub 2017 Dec 9. PMID: 29116687.

Besnard C, Schmitt C, Galmiche-Rolland L, et al. Bone Marrow Transplantation in Congenital Erythropoietic Porphyria: Sustained Efficacy but Unexpected Liver Dysfunction. *Biol Blood Marrow Transplant.* 2020 Apr;26(4):704-711. doi: 10.1016/j.bbmt.2019.12.005. Epub 2019 Dec 14. PMID:3184356.

Thomas C, Ged C, Nordmann Y, et al. Correction of congenital erythropoietic porphyria by bone marrow transplantation. *J Pediatr.* 1996;129:453–456.

Zix-Kieffer I, Langer B, Eyer D et al. Successful cord blood stem cell transplantation for congenital erythropoietic porphyria (Guthrie's disease). *Bone Marrow Transplant.* 1996;18:217–220.

Tezcan I, Xu W, Gurgey A, et al. Congenital erythropoietic porphyria successfully treated by allogeneic bone marrow transplantation. *Blood.* 1998;92:4053–4058.

Shaw PH, Mancin JA, McConnell JP et al. Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: a case report and review of the literature. *Bone Marrow Transplant.* 2001;27:101–105.

Phillips JD, Steensma DP, Pulsipher MA, et al. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. *Blood.* 2007; 109:2618–2621.

Tabije SM, Stevenson OE, Abdullah A, et al. Allogeneic bone marrow transplantation in a 7-year-old girl with congenital erythropoietic porphyria: a treatment dilemma. *Br J Dermatol.* 2007;156:567–571.

Faraci M, Morreale G, Boeri E, et al. Unrelated HSCT in an adolescent affected by congenital erythropoietic porphyria. *Pediatr Transplant.* 2008;12:117–120.

Lebreuilly-Solier I, Morice A, Achier A, et al. Congenital erythropoietic porphyria treated by haematopoietic stem cell allograft. *Ann Dermatol Venerol.* 2010;137:635–639. [in French].

Singh S, Khanna N, Kumar L. Bone marrow transplantation improves symptoms of congenital erythropoietic porphyria even when done post puberty. *Indian J Dermatol Venerol Leprol.* 2012;78:108–111.

Martinez Peinado C, Diaz de Heredia C, To-Figueroa J, et al. Successful treatment of congenital erythropoietic porphyria using matched unrelated hematopoietic stem cell transplantation. *Pediatr Dermatol.* 2013;30:484–489.

Karakurt N, Tavli B, Azik F, et al. Successful hematopoietic stem cell transplantation in a child with congenital erythropoietic porphyria due to a mutation in GATA-1. *Pediatr Transplant.* 2015;19:803–805.




Figure 1 – Evolution of patient #3 total erythrocytes porphyrins level. Green area indicates the normal range. HSCT: hematopoietic stem cell transplantation.

(3.529 nmol/mmol creatinine) to induce severe symptomatology. It is therefore important to target full myeloid chimerism and normal erythrocyte porphyrins, especially in CEP patients.

In conclusion, HSCT should be evaluated for high-risk adults and young adult patients, with EPP and liver involvement. If possible HSCT must be performed before LT to prevent long-term complications inherent to solid organ transplantation; after LT it is necessary to prevent the inevitable relapse of the disease.

Conflicts of interest

The authors declare no competing financial interests.

Author contribution

C.F and F.S. generated the idea, collected the data and edited the manuscript; A.P. gave his contribution as experts in the porphyria's field. M.B., participated in patient treatment and follow-up at regional study sites. All authors read and approved the final manuscript.

Acknowledgments

The authors would like to thank Juliette Villemonteix, Pauline Houssel-Debry, Olivier Roux, Juliette Delforge, Anne Brignier, Nathalie Parquet, Régis Peffault De Latour, Gerard Socie and Laurent Gouya for their contribution and help in data collection.

REFERENCES

1. Dawe R. An overview of the cutaneous porphyrias. *F1000Res*. 2017;30(6):1906. <https://doi.org/10.12688/f1000research.10101.1>. PMID: 29152226; PMCID: PMC5664971.
2. APF. Erythropoietic protoporphyria (EPP) and X-Linked Porphyria (XLP). American Porphyria Foundation (APF). Accessed October 14, 2022.
3. Balwani M. Erythropoietic protoporphyria and X-linked protoporphyria: pathophysiology, genetics, clinical manifestations, and management. *Mol Genet Metab*. 2019;128(3):298–303. <https://doi.org/10.1016/j.ymgme.2019.01.020>. Epub 2019 Jan 24. PMID: 30704898; PMCID: PMC6656624.
4. Bloomer JR. The liver in protoporphyria. *Hepatology*. 1988;8:402–7. [PubMed: 3281889].
5. Bloomer JR. Hepatic protoporphyrin metabolism in patients with advanced protoporphyrin liver disease. *Yale J Biol Med*. 1997;70:323–30. [PubMed: 9626752].
6. Wahlin S, Aschan J, Bjornstedt M, Broome U, Harper P. Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis. *J Hepatol*. 2007;46:174–9.
7. McGuire BM, Bonkovsky HL, Carithers Jr RL, Chung RT, Goldstein LI, Lake JR, et al. Liver transplantation for erythropoietic protoporphyria liver disease. *Liver Transpl*. 2005;11:1590–6.
8. Wahlin S, Harper P. The role for BMT in erythropoietic protoporphyria. *Bone Marrow Transplant*. 2010;45:393–4. [PubMed: 19525986].
9. Dupuis-Girod S, Akkari V, Ged C, et al. Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria Gunther disease. *Eur J Pediatr*. 2005;164:104–7.
10. Harada FA, Shwayder TA, Desnick RJ, Lim HW. Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation. *J Am Acad Dermatol*. 2001;45:279–82.